Literature DB >> 24990232

MicroRNA-24 regulates macrophage behavior and retards atherosclerosis.

Karina Di Gregoli1, Nicholas Jenkins1, Rebecca Salter1, Stephen White1, Andrew C Newby1, Jason L Johnson2.   

Abstract

OBJECTIVE: Our recent studies have highlighted membrane type-1 matrix metalloproteinase (MMP)-14 as a selective marker for an invasive subset of macrophages potentially related to atherosclerotic plaque progression. Moreover, colony stimulating factors (CSF) may exert divergent effects on macrophage MMP expression, possibly through microRNAs. We, therefore, aim to identify and test the pathophysiological role of microRNAs, which modulate macrophage MMP-14 expression in atherosclerotic plaque progression. APPROACH AND
RESULTS: Compared with macrophage CSF-differentiated macrophages, granulocyte/macrophage CSF-matured macrophages exhibited reduced MMP-14 mRNA levels but increased protein expression and activity, which resulted in heightened macrophage invasion. MicroRNA-24, identified to target MMP-14, was accordingly increased in macrophage CSF compared with granulocyte/macrophage CSF macrophages. Silencing microRNA-24 in macrophage CSF macrophages significantly increased MMP-14 expression and enhanced their invasive capacity, mimicking granulocyte/macrophage CSF macrophages, and suggesting that granulocyte/macrophage CSF modulates MMP-14 protein expression and subsequent macrophage invasion in a microRNA-24-dependent manner. In human coronary atherosclerotic plaques, increased MMP-14 protein expression in foam cell macrophages was associated with lesions exhibiting histological characteristics associated with an unstable phenotype. Furthermore, microRNA-24 expression in these atherosclerotic plaques was inversely related to MMP-14 protein expression. Moreover, stable plaques contained higher microRNA-24 levels than unstable plaques, and microRNA-24 colocalized with foam cell macrophages that exhibited low MMP-14 protein expression. Finally, in atherosclerotic mice (apolipoprotein E-deficient), microRNA-24 inhibition increased plaque size and macrophage MMP-14 expression.
CONCLUSIONS: Taken together, our data demonstrates that downregulation of microRNA-24 promotes an invasive macrophage subset and plays a novel regulatory role in MMP-14 proteolytic activity and, therefore, plaque stability, highlighting its therapeutic potential.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  atherosclerosis; macrophages; matrix metalloproteinases; microRNAs

Mesh:

Substances:

Year:  2014        PMID: 24990232     DOI: 10.1161/ATVBAHA.114.304088

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  37 in total

Review 1.  Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis?

Authors:  Leonne E Philippen; Ellen Dirkx; Jan B M Wit; Koos Burggraaf; Leon J de Windt; Paula A da Costa Martins
Journal:  Mol Ther       Date:  2015-07-28       Impact factor: 11.454

Review 2.  Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis.

Authors:  Mingyi Wang; Soo Hyuk Kim; Robert E Monticone; Edward G Lakatta
Journal:  Hypertension       Date:  2015-02-09       Impact factor: 10.190

Review 3.  MicroRNA-mediated mechanisms of the cellular stress response in atherosclerosis.

Authors:  Andreas Schober; Maliheh Nazari-Jahantigh; Christian Weber
Journal:  Nat Rev Cardiol       Date:  2015-04-07       Impact factor: 32.419

4.  Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor.

Authors:  Yaozu Xiang; Jijun Cheng; Dandan Wang; Xiaoyue Hu; Yi Xie; Jeremiah Stitham; Gourg Atteya; Jing Du; Wai Ho Tang; Seung Hee Lee; Kristen Leslie; Geralyn Spollett; Zejian Liu; Erica Herzog; Raimund I Herzog; Jun Lu; Kathleen A Martin; John Hwa
Journal:  Blood       Date:  2015-03-26       Impact factor: 22.113

5.  MicroRNA-24 inhibits the proliferation and migration of endothelial cells in patients with atherosclerosis by targeting importin-α3 and regulating inflammatory responses.

Authors:  Ye Zheng; Yongxing Li; Gang Liu; Xiangqian Qi; Xufen Cao
Journal:  Exp Ther Med       Date:  2017-10-23       Impact factor: 2.447

Review 6.  Epigenetic reprogramming in atherosclerosis.

Authors:  Vincenzo Grimaldi; Maria Teresa Vietri; Concetta Schiano; Antonietta Picascia; Maria Rosaria De Pascale; Carmela Fiorito; Amelia Casamassimi; Claudio Napoli
Journal:  Curr Atheroscler Rep       Date:  2015       Impact factor: 5.113

Review 7.  Emerging Roles for MicroRNAs in Diabetic Microvascular Disease: Novel Targets for Therapy.

Authors:  Yu Zhang; Xinghui Sun; Basak Icli; Mark W Feinberg
Journal:  Endocr Rev       Date:  2017-04-01       Impact factor: 19.871

Review 8.  Nanomedicines for dysfunctional macrophage-associated diseases.

Authors:  Hongliang He; Shobha Ghosh; Hu Yang
Journal:  J Control Release       Date:  2017-01-03       Impact factor: 9.776

Review 9.  Atherosclerosis.

Authors:  Hong Lu; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-03       Impact factor: 8.311

Review 10.  Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?

Authors:  Peter Willeit; Philipp Skroblin; Stefan Kiechl; Carlos Fernández-Hernando; Manuel Mayr
Journal:  Eur Heart J       Date:  2016-04-20       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.